Home » Stocks » RCUS

Arcus Biosciences, Inc. (RCUS)

Stock Price: $32.23 USD -0.90 (-2.72%)
Updated Apr 19, 2021 11:05 AM EDT - Market open
Market Cap 2.35B
Revenue (ttm) 77.52M
Net Income (ttm) -122.86M
Shares Out 64.92M
EPS (ttm) -2.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $32.23
Previous Close $33.13
Change ($) -0.90
Change (%) -2.72%
Day's Open 32.68
Day's Range 32.16 - 33.35
Day's Volume 73,338
52-Week Range 16.69 - 42.36

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented progression-free su...

1 week ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...

1 week ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...

3 weeks ago - Business Wire

Arcus Biosciences, Inc. (RCUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt...

1 month ago - Zacks Investment Research

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...

1 month ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...

1 month ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results fo...

1 month ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management wil...

2 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...

2 months ago - Business Wire

Arcus Biosciences Inc. disclosed Monday that Gilead Sciences Inc. boosted its stake in the oncology-focused biopharmaceutical company, through the purchase of $220.35 million worth of stock. Arcus share...

Other stocks mentioned: GILD
2 months ago - Market Watch

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Gilead Science...

2 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...

2 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented preliminary data fr...

3 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...

3 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that preliminary da...

3 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Andrew Perlman...

3 months ago - Business Wire

Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...

4 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, and WuXi Biologics (2269.HK), a glo...

4 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management wil...

5 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...

5 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced financial results f...

5 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced a collaboration wit...

Other stocks mentioned: AZN
5 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Jennifer Jarre...

6 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.

7 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.

8 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.

8 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.

8 months ago - Business Wire

Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

8 months ago - Zacks Investment Research

Arcus Biosciences, Inc.: An Oncology Stock With Newfound Prominence

9 months ago - Seeking Alpha

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create bes...

9 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bob Goeltz wil...

9 months ago - Business Wire

Is (RCUS) Outperforming Other Medical Stocks This Year?

9 months ago - Zacks Investment Research

Is (RCUS) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

Arcus Biosciences (RCUS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

The development-stage biopharma is bouncing back from a recent stock dip.

10 months ago - The Motley Fool

Investors expecting a buyout offer were disappointed by the collaboration agreement Gilead Sciences offered.

10 months ago - The Motley Fool

The deal gives Gilead access to a new pipeline of potential cancer immunotherapies.

Other stocks mentioned: GILD
10 months ago - The Motley Fool

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -12.50% and -12.50%, respectively, for the quarter ended March 2020.

11 months ago - Zacks Investment Research

Is (RCUS) Outperforming Other Medical Stocks This Year?

11 months ago - Zacks Investment Research

Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

11 months ago - Zacks Investment Research

Shares of Arcus Biosciences Inc. RCUS, +88.44% soared 87% in trading on Thursday after people familiar with the matter told Bloomberg News that Gilead Sciences Inc.

1 year ago - Market Watch

The two companies are apparently discussing either an equity purchase or some other form of cooperation.

Other stocks mentioned: GILD
1 year ago - The Motley Fool

Arcus Biosciences stock rocketed to a record high Thursday on reports suggesting Gilead Sciences could be interested in acquiring a stake in the Alphabet-backed biotech company.

1 year ago - Investors Business Daily

Does Arcus Biosciences, Inc. (RCUS) have what it takes to be a top stock pick for momentum investors?

1 year ago - Zacks Investment Research

Arcus Biosciences stock is on fire in response to a possible partnership deal with Gilead Sciences.

1 year ago - The Motley Fool

Arcus Biosciences (RCUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

1 year ago - Zacks Investment Research

Arcus Biosciences Anti-TIGIT Candidate Puts Company In The Shop Window

1 year ago - Seeking Alpha

Top Ranked Momentum Stocks to Buy for March 13th

Other stocks mentioned: BCYC, GSX, VIRT
1 year ago - Zacks Investment Research

Efforts to contain COVID-19 are putting the entire biopharmaceutical industry in a jam.

Other stocks mentioned: BIIB
1 year ago - The Motley Fool

About RCUS

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combi... [Read more...]

Industry
Biotechnology
IPO Date
Mar 15, 2018
Stock Exchange
NYSE
Ticker Symbol
RCUS
Full Company Profile

Financial Performance

In 2020, RCUS's revenue was $77.52 million, an increase of 416.78% compared to the previous year's $15.00 million. Losses were -$122.86 million, 45.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for RCUS stock is "Strong Buy." The 12-month stock price forecast is 53.20, which is an increase of 65.06% from the latest price.

Price Target
$53.20
(65.06% upside)
Analyst Consensus: Strong Buy